Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial

J.B. Bachet 1, * O. Lucidarme 2 C.B. Levache 3 E. Barbier 4, 5 J.L. Raoul 6 T. Lecomte 7 C. Desauw 8 F. Brocard 9 S. Pernot 10, 11, 12 G. Breysacher 10, 11, 12 J.P. Lagasse 13 F. Di Fiore 14 P.L. Etienne 15 O.J.M. Dupuis 16 A. Aleba 17 C. Lepage 18, 5 J. Taieb 19 L. Dahan 20 D. Auby F. Khemissa F. Ghiringhelli 21 S. Nguyen A. Bedjaoui E. Terrebonne 22 J. Thaury 23 M. Baconnier 24 
Abstract : Aim of the study The optimal therapeutic strategy in patients with rectal cancer and synchronous unresectable metastases remains unknown. We evaluated the efficacy of FOLFIRINOX induction therapy in this setting. Patients and methods Chemotherapy-naïve patients received at least 8 cycles of FOLFIRINOX. The primary end-point was the 4-month disease control (4 m DC) rate. Tumour responses were centrally reviewed and assessed by computed tomography scan for metastases (Response Evaluation Criteria in Solid Tumours criteria) and magnetic resonance imaging for rectal tumorus. With a Simon 2-stage design and a targeted (H1) 4 m DC > 75%, 65 patients were enrolled from July 2012 to February 2015: male, 78%; median age, 61 years; performance status, 0–1, 98%; liver metastases, 92%; ≥2 metastatic sites, 63%. Results Fifty-six (85%) of the 65 patients received the 8 planned FOLFIRINOX cycles. The primary objective was achieved (4 m DC rate: 94%; 95% confidence interval [CI], 86.3–97.8). Primary tumour symptoms decreased from 72% at baseline to 10% at 4 months. Response rate was 86%, and a >70% primary tumour volume decrease was seen in 63% of patients. Forty-four patients (68%) had at least one grade 3 side-effect; no toxic deaths occurred. Median follow-up was 35.0 months (95% CI, 31.3–43.7). Median progression-free survival and overall survival were 10.9 m (95% CI, 8.8–12.9) and 33.4 m (95% CI, 22.6–38.2), respectively. Conclusion Upfront FOLFIRINOX is feasible and allows good local and distant control. It therefore offers the opportunity to choose the best therapeutic strategy for each patient and to personalise treatment according to the local and distant efficacy results of this induction step. Trial registration, NCT01674309.
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : LNC - université de Bourgogne Connectez-vous pour contacter le contributeur
Soumis le : mercredi 19 décembre 2018 - 11:29:33
Dernière modification le : vendredi 5 août 2022 - 03:36:47



J.B. Bachet, O. Lucidarme, C.B. Levache, E. Barbier, J.L. Raoul, et al.. FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial. European Journal of Cancer, Elsevier, 2018, 104, pp.108-116. ⟨10.1016/j.ejca.2018.09.006⟩. ⟨hal-01960176⟩



Consultations de la notice